Skip to main content
Premium Trial:

Request an Annual Quote

Douglas Amorese, Lee Hood, Trevor Hawkins

Premium
Douglas Amorese has become vice president of research and development at NuGen Technologies, a new position, the DNA amplification and labeling company said this week. Most recently, he was director of research and development for Agilent Technologies' genomics group, where he was responsible for new product development projects related to the company's DNA microarray business. Prior to that, he held various positions at DuPont and Life Technologies. Amorese holds a PhD in biochemistry from Colorado State University.
 

 
Lee Hood has joined the advisory committee of venture capital firm InterWest Partners, the company said this week. He had already been a member of InterWest’s life sciences advisory committee. Hood is president and co-founder of the Institute for Systems Biology.
 

 
Trevor Hawkins has become chairman and CEO of ProGenTech, the company said last week. Previously, he was CEO of Philips Molecular Healthcare and held executive positions at GE and at MDS. Hawkins is also the former director of the US Department of Energy’s Joint Genome Institute.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.